From the perspective of Ken Mayer (Founder/CEO) and Electrome, the convergence of new clinical data and corporate financial stability creates a strategic "perfect storm" for the commercialization of an ActiPatch-branded or licensed product.
Here is how these three specific pillars facilitate the path to market:
1. The Stanford Thumb Study: Validation for Small-Joint High-Frequency Markets
The recent Stanford University study—which demonstrated that ActiPatch’s Pulsed Shortwave Therapy (PSWT) significantly reduces pain and improves function in thumb carpometacarpal (CMC) osteoarthritis—is a commercial "game changer."
Targeted Product Design: For Ken Mayer, this validates the need for a specialized, ergonomic "ActiPatch Thumb" device. The study showed that even brief overnight use (8 hours) led to sustained relief, allowing Electrome to market a high-compliance, low-profile product.
Medical Credibility: Having the Stanford name attached to the clinical efficacy of the 27.12 MHz frequency provides the high-level medical "blessing" needed to move beyond OTC retail and into the hands of orthopedic surgeons and hand therapists.
2. The Veterinary Study: Expanding the "Patient" Base
The successful veterinary study (showing a 45% reduction in pain and increased range of motion in canines) opens a secondary, high-growth revenue stream that bypasses many of the hurdles of human healthcare.
Proof of Biological Action: For Electrome, the animal data is a powerful rebuttal to the "placebo effect." Animals don't experience the placebo effect; if the device works on a dog’s hip, the physiological mechanism (neuromodulation via inductive coupling) is indisputable.
The Vet-Med Channel: Ken Mayer can leverage this to license ActiPatch technology to veterinary distributors, creating a fast-to-market "Animal ActiPatch" line that supports the brand's overall manufacturing volume and profitability.
3. Current Financials: Rebuilding Institutional Trust
Getting BioElectronics Corp (BIEL) financials current is the administrative "key" that unlocks
Electrome’s ability to scale.
Uplisting and Investment: Current financials allow the company to move toward higher-tier exchanges (like the OTCQB), making the stock more attractive to institutional investors and potential acquisition partners.
Strategic Partnerships: Large-scale licensing deals (like those previously explored with STADA or potential new OEMs) require transparent, audited books. By being "current," Electrome can negotiate from a position of strength, proving they have the stability to support global supply chains and long-term royalties.
Here is how these three specific pillars facilitate the path to market:
1. The Stanford Thumb Study: Validation for Small-Joint High-Frequency Markets
The recent Stanford University study—which demonstrated that ActiPatch’s Pulsed Shortwave Therapy (PSWT) significantly reduces pain and improves function in thumb carpometacarpal (CMC) osteoarthritis—is a commercial "game changer."
Targeted Product Design: For Ken Mayer, this validates the need for a specialized, ergonomic "ActiPatch Thumb" device. The study showed that even brief overnight use (8 hours) led to sustained relief, allowing Electrome to market a high-compliance, low-profile product.
Medical Credibility: Having the Stanford name attached to the clinical efficacy of the 27.12 MHz frequency provides the high-level medical "blessing" needed to move beyond OTC retail and into the hands of orthopedic surgeons and hand therapists.
2. The Veterinary Study: Expanding the "Patient" Base
The successful veterinary study (showing a 45% reduction in pain and increased range of motion in canines) opens a secondary, high-growth revenue stream that bypasses many of the hurdles of human healthcare.
Proof of Biological Action: For Electrome, the animal data is a powerful rebuttal to the "placebo effect." Animals don't experience the placebo effect; if the device works on a dog’s hip, the physiological mechanism (neuromodulation via inductive coupling) is indisputable.
The Vet-Med Channel: Ken Mayer can leverage this to license ActiPatch technology to veterinary distributors, creating a fast-to-market "Animal ActiPatch" line that supports the brand's overall manufacturing volume and profitability.
3. Current Financials: Rebuilding Institutional Trust
Getting BioElectronics Corp (BIEL) financials current is the administrative "key" that unlocks
Electrome’s ability to scale.
Uplisting and Investment: Current financials allow the company to move toward higher-tier exchanges (like the OTCQB), making the stock more attractive to institutional investors and potential acquisition partners.
Strategic Partnerships: Large-scale licensing deals (like those previously explored with STADA or potential new OEMs) require transparent, audited books. By being "current," Electrome can negotiate from a position of strength, proving they have the stability to support global supply chains and long-term royalties.
2
